Control Bionics Inc.

Control Bionics Inc. develops advanced assistive technology products that enhance communication for individuals facing complex physical and communication challenges, focusing on innovative solutions for those with disabilities. Founded in 2006 in Milford, US, Control Bionics Inc. specializes in assistive technology for communication.

The company has successfully completed 5 deals, with its latest funding round being an IPO on October 19, 2020, raising AUD 50 mn. Peter Ford is one of the founders, and the current CEO is Jeremy Steele. The company operates globally, with a focus on markets including the United States and Australia. Control Bionics specializes in a suite of advanced assistive technology products designed to enhance communication for individuals with complex physical and communication challenges.

The company's core offerings include the NeuroNode Trilogy, NeuroNode Duo, EyeGaze Duo, and Uno Touch, each engineered to facilitate user interaction through various modalities such as touch, eye gaze, and electromyography (EMG). The NeuroNode Trilogy stands out as a dedicated speech generating device that allows users to communicate up to 47% faster than traditional methods, catering to individuals with conditions like paralysis, cerebral palsy, and spinal cord injuries. These products are tailored for a diverse client base, including patients, healthcare providers, and rehabilitation centers across Australia, the United States, Canada, and Japan, effectively supporting a wide range of users from children to adults affected by degenerative neurological conditions. Control Bionics generated revenue of AUD 3,972,119 in 2021, with an EBITDA of AUD -3,281,916.

The company generates revenue through the sale of its assistive technology products, which are classified under specific billing codes for insurance reimbursement purposes. The transaction structure primarily involves direct sales to end-users as well as partnerships with healthcare providers, ensuring a streamlined acquisition process for clients in need. The NeuroNode Trilogy and its related products are positioned as premium solutions within the assistive technology sector, reflecting a commitment to quality and innovation. The company also offers various mounting systems and accessories, complementing its primary products and enhancing user experience.

The pricing structure is designed to accommodate the needs of both individual consumers and institutional clients, facilitating access to essential communication tools for those with significant disabilities. Control Bionics is focused on expanding its product line with new assistive technology solutions and aims to enter new markets, particularly targeting Asia and Europe by 2023. The recent IPO raising AUD 50 mn will be utilized to support product development and facilitate market entry strategies. The company anticipates launching additional products designed to enhance user experience and meet the growing demand for innovative communication solutions in the coming years.